Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk

Authors Ajikumar V Aryangat, John E Gerich

Published 9 March 2010 Volume 2010:6 Pages 145—155


Review by Single-blind

Peer reviewer comments 4

Ajikumar V Aryangat, John E Gerich
University of Rochester, Rochester, New York, USA
Abstract: Hyperglycemia is a major risk factor for both the microvascular and macrovascular complications in  patients with type 2 diabetes. This review summarizes the cardiovascular results of large outcomes trials in diabetes and presents new evidence on the role of hyperglycemia, with particular emphasis on postprandial hyperglycemia, in adverse cardiovascular outcomes in patients with type 2 diabetes. Treatment options, including the new dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 mimetics that primarily target postprandial hyperglycemia, are also discussed. Hyperglycemia increases cardiovascular mortality, and reducing hyperglycemia lowers cardiovascular risk parameters. Control of both fasting and postprandial hyperglycemia is necessary to achieve optimal glycated hemoglobin control. Therefore, antihyperglycemic agents that preferentially target postprandial hyperglycemia, along with those that preferentially target fasting hyperglycemia, are strongly suggested to optimize individual diabetes treatment strategies and reduce complications.
Keywords: postprandial hyperglycemia, diabetes mellitus, drugs, cardiovascular risk

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Readers of this article also read:

Stiffness of the large arteries in individuals with and without Down syndrome

Rodrigues AN, Coelho LC, Goncalves WLS, Gouvea SA, Vasconcellos MJR, Cunha RS, Abreu GR

Vascular Health and Risk Management 2011, 7:375-381

Published Date: 9 June 2011

Hypothyroidism and the risk of lower extremity arterial disease

Michael A Mazzeffi, Hung-Mo Lin, Brigid C Flynn, et al

Vascular Health and Risk Management 2010, 6:957-962

Published Date: 20 October 2010

Diagnostic accuracy of dual-source CT angiography and coronary risk stratification

Xia Yang, Lu-yue Gai, Ping Li, et al

Vascular Health and Risk Management 2010, 6:935-941

Published Date: 14 October 2010

Impact of a diabetic foot care education program on lower limb amputation rate

Abdullah M Al-Wahbi

Vascular Health and Risk Management 2010, 6:923-934

Published Date: 11 October 2010

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo

Vascular Health and Risk Management 2010, 6:671-690

Published Date: 5 August 2010

Aspirin and clopidogrel resistance: methodological challenges and opportunities

Armen Yuri Gasparyan

Vascular Health and Risk Management 2010, 6:109-112

Published Date: 2 March 2010

On the antiatherogenic effects of vitamin E: the search for the Holy Grail

Francesco Galli, Dimitrios Kirmizis, Dimitrios Chatzidimitriou

Vascular Health and Risk Management 2010, 6:69-71

Published Date: 16 February 2010

Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care

Frederic Kontny, Terje Risanger, Arne Bye, et al

Vascular Health and Risk Management 2010, 6:31-38

Published Date: 15 January 2010